Development of Tumor Markers for Breast Cancer Immunotherapy

Qianqian Fang(Qinghai University Affiliated Hospital), Jiuda Zhao(Qinghai University), Guoshuang Shen(Qinghai University Affiliated Hospital), Qiqi Xie(Jinan University), Dengfeng Ren(Qinghai University Affiliated Hospital), Yumei Guan(Qinghai University Affiliated Hospital), Xinlan Liu(Yunnan Agricultural University), Zhilin Liu(Nanjing Agricultural University), Fuxing Zhao(Qinghai University Affiliated Hospital), Fei Ma(Chinese Academy of Medical Sciences & Peking Union Medical College)
Current Molecular Medicine
May 9, 2023
10.2174/1566524023666230508152817
Cited by 2

Related Papers

Induction of Pyroptosis and Its Implications in Cancer Management
|Frontiers in Oncology|2019|274
Interleukin-6: An Autocrine Regulator of the Mouse Cumulus Cell-Oocyte Complex Expansion Process
|Endocrinology|2009|143
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
|Nature Medicine|2024|121
In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
|Frontiers in Oncology|2022|119
MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1
|Oncotarget|2015|96